Who are the top shareholders of the Concord Drugs?

The top shareholders of Concord Drugs include promoter Nagi Reddy Seelam with 28.61% ownership, while individual investors hold 43.33%. The highest public shareholder is Pradeep Kumar Jain at 1.89%, and there are no mutual funds or foreign institutional investors involved.

The top shareholders of Concord Drugs include the promoters, who hold the majority of the shares. The promoter with the highest holding is Nagi Reddy Seelam, who owns 28.61% of the company. Additionally, individual investors collectively hold 43.33% of the shares. The highest public shareholder is Pradeep Kumar Jain, with a holding of 1.89%. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

how big is Concord Drugs?

As of Jun 06, Concord Drugs Ltd has a market capitalization of 31.51 Cr, with recent net sales of 45.25 Cr and a net profit of 0.34 Cr over the last four quarters. The latest balance sheet shows shareholder's funds at 33.82 Cr and total assets of 58.81 Cr.

Market Cap: <BR>As of Jun 06, Concord Drugs Ltd has a market capitalization of 31.51 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, the sum of Net Sales is 45.25 Cr, and the sum of Net Profit is 0.34 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: <BR>This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 33.82 Cr, and the Total Assets amount to 58.81 Cr.

When is the next results date for Concord Drugs?

No Upcoming Board Meetings

Who are in the management team of Concord Drugs?

As of March 2022, the management team of Concord Drugs includes S Nagi Reddy (Chairman & Managing Director), K Ramchandra Reddy (Independent Director), Koni Reddy (Whole Time Director & CFO), S. Nagavenkata Hareesh (Independent Director), S. Manoj Kumar Reddy (Whole-time Director), and Summela Kasu (Independent Director). Each member contributes to the company's governance and operations.

As of March 2022, the management team of Concord Drugs includes the following individuals:<BR><BR>1. S Nagi Reddy - Chairman & Managing Director<BR>2. K Ramchandra Reddy - Independent Director<BR>3. Koni Reddy - Whole Time Director & CFO<BR>4. S. Nagavenkata Hareesh - Independent Director<BR>5. S. Manoj Kumar Reddy - Whole-time Director<BR>6. Summela Kasu - Independent Director<BR><BR>Each member plays a crucial role in the governance and operational management of the company.

What does Concord Drugs do?

Concord Drugs Ltd is a micro-cap pharmaceutical company established in 1995, specializing in finished pharmaceutical formulations. As of March 2025, it reported net sales of 10 Cr and a market cap of Rs 31 Cr.

Overview: <BR>Concord Drugs Ltd is a pharmaceutical company that specializes in the manufacturing of finished pharmaceutical formulations, operating within the micro-cap segment of the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Concord Drugs Ltd was established in 1995. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 10 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 31 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 33.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.50 <BR>Return on Equity: 1.00% <BR>Price to Book: 0.96 <BR><BR>Contact Details: <BR>Address: Survey No 249 Brahmanapally V, Hayathnagar M Ranga Reddy Telangana : 501511 <BR>Tel: 91-40-24036379 <BR>Email: concorddrugsltd@gmail.com <BR>Website: http://www.concorddrugs.in

Has Concord Drugs declared dividend?

No Dividend History Available

Who are the peers of the Concord Drugs?

Peers of Concord Drugs include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Concord Drugs has below-average management risk, growth, and capital structure compared to its peers, with a 1-year return of -13.79%.

Peers: The peers of Concord Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Veerhealth Care, Colinz Labs, Vineet Laborator, Zenith Health, and Ishita Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Vineet Laborator. Below Average management risk is noted at Concord Drugs, Veerhealth Care, Colinz Labs, Zenith Health, and Ishita Drugs. Growth is Excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Concord Drugs, Divi's Lab., Torrent Pharma, Veerhealth Care, Colinz Labs, Vineet Laborator, Zenith Health, and Ishita Drugs. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is noted at Torrent Pharma, Veerhealth Care, Colinz Labs, and Zenith Health, and Below Average capital structure is observed at Concord Drugs, Vineet Laborator, and Ishita Drugs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the peer with the lowest is Vineet Laborator at -46.35%. Concord Drugs has a 1-year return of -13.79%, which is higher than Vineet Laborator's but lower than all other peers. Additionally, Veerhealth Care, Vineet Laborator, and Ishita Drugs have negative six-month returns.

What is the technical trend for Concord Drugs?

As of June 5, 2025, Concord Drugs is in a mildly bearish trend, with daily moving averages and weekly Bollinger Bands indicating bearish signals, while mixed signals from weekly MACD and KST, along with a neutral RSI, suggest moderate bearish strength influenced by recent price action.

As of 5 June 2025, the technical trend for Concord Drugs has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing a mildly bearish signal. While the weekly MACD and KST are mildly bullish, the monthly indicators remain bearish, suggesting mixed signals across different time frames. The RSI shows no signals, indicating a lack of momentum in either direction. Overall, the strength of the bearish trend is moderate, influenced by the recent price action and the broader market context.

Are Concord Drugs latest results good or bad?

Concord Drugs' latest results are positive, showing a profit after tax of Rs 0.16 crore, a turnaround from a loss last year, and the highest net sales in five quarters. While growth has slowed year-over-year, the overall financial health is improving, leading to a 'Hold' stock recommendation.

Concord Drugs' latest results can be viewed as a positive development for the company. They reported a profit after tax (PAT) of Rs 0.16 crore for the latest six-month period, which is a significant turnaround from a loss of Rs 0.04 crore in the previous year. This indicates that the company has made substantial progress in improving its profitability.<BR><BR>Additionally, net sales for the quarter reached Rs 13.61 crore, marking the highest level in the last five quarters, although the year-over-year growth rate has slowed compared to the previous year. The overall financial performance has shown improvement, with the company's score rising from -4 to 3 over the past three months, suggesting a stabilization in its financial health.<BR><BR>The stock call remains a 'Hold,' reflecting a cautious but optimistic sentiment in the market regarding Concord Drugs' performance. Overall, while there are areas for improvement, the recent results indicate a positive trend for the company.

How has been the historical performance of Concord Drugs?

Concord Drugs has experienced a declining trend in net sales and profits over the past four years, with net sales at 45.25 Cr in March 2025, down from 59.06 Cr in March 2022. Despite a slight increase in some metrics in 2025, overall financial performance remains challenging.

Answer:<BR>The historical performance of Concord Drugs shows a declining trend in net sales and profits over the past four years.<BR><BR>Breakdown:<BR>Concord Drugs reported net sales of 45.25 Cr in March 2025, a slight increase from 44.93 Cr in March 2024, but a decrease from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. Total operating income mirrored this trend, remaining at 45.25 Cr in March 2025, up from 44.93 Cr in March 2024, but down from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. The total expenditure, excluding depreciation, was 41.11 Cr in March 2025, up from 40.88 Cr in March 2024, but down from 47.50 Cr in March 2023 and 53.37 Cr in March 2022. Operating profit (PBDIT) was 4.14 Cr in March 2025, a slight increase from 4.05 Cr in March 2024, but lower than 4.59 Cr in March 2023 and 5.69 Cr in March 2022. Profit before tax was 0.69 Cr in March 2025, up from 0.63 Cr in March 2024, but significantly down from 1.25 Cr in March 2023 and 2.25 Cr in March 2022. Profit after tax also decreased to 0.34 Cr in March 2025 from 0.47 Cr in March 2024, 0.99 Cr in March 2023, and 1.59 Cr in March 2022. The total assets of the company increased to 65.14 Cr in March 2025 from 58.81 Cr in March 2024, while total liabilities rose to 65.14 Cr from 58.81 Cr in the same period. Cash flow from operating activities was 3.00 Cr in March 2025, showing improvement from 0.00 Cr in March 2024, while cash flow from investing activities was -2.00 Cr, and cash flow from financing activities was -1.00 Cr. Overall, the financial metrics indicate a challenging performance trajectory for Concord Drugs over the past four years.

Should I buy, sell or hold Concord Drugs?

Is Concord Drugs overvalued or undervalued?

As of December 2, 2025, Concord Drugs is considered undervalued with a PE Ratio of 135.16 and a PEG Ratio of 0.63, outperforming peers like Sun Pharma and Divi's Lab, and achieving a year-to-date return of 106.29% compared to the Sensex's 8.96%.

As of 2 December 2025, Concord Drugs has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, particularly in comparison to its peers in the pharmaceuticals and biotechnology sector. Notable ratios include a PE Ratio of 135.16, an EV to EBITDA of 20.90, and a PEG Ratio of 0.63, indicating potential growth relative to its price.<BR><BR>In comparison to its peers, Concord Drugs stands out with its attractive valuation, while Sun Pharma has a PE of 37.36 and an EV to EBITDA of 24.69, and Divi's Lab is even more expensive with a PE of 68.62 and an EV to EBITDA of 51.56. Despite a recent decline in stock price, Concord Drugs has significantly outperformed the Sensex over various periods, including a year-to-date return of 106.29% compared to the Sensex's 8.96%. This performance reinforces the view that the company is undervalued relative to its growth potential.

Which are the latest news on Concord Drugs?

Why is Concord Drugs falling/rising?

As of 04-Dec, Concord Drugs Ltd's stock price is rising to 77.60, reflecting a 3.0% increase after a trend reversal. However, a significant drop in investor participation, with delivery volume down 66.74%, suggests caution among investors.

As of 04-Dec, Concord Drugs Ltd's stock price is rising, currently at 77.60, reflecting a change of 2.26 (3.0%) upwards. This increase comes after a trend reversal, as the stock has gained after four consecutive days of decline. Additionally, the stock outperformed its sector by 2.71% today, indicating a positive performance relative to its peers.<BR><BR>In terms of intraday performance, the stock reached a high of Rs 78.45, marking a 4.13% increase during the trading session. Despite this positive movement, it is important to note that the stock has experienced a significant drop in investor participation, with delivery volume falling by 66.74% against the 5-day average. This decline in trading activity may suggest caution among investors.<BR><BR>Overall, the recent rise in Concord Drugs Ltd's stock price can be attributed to the trend reversal and its outperformance against the sector, despite the noted decrease in investor participation.